MX371154B - Composicion nasal de vacuna para la influenza. - Google Patents

Composicion nasal de vacuna para la influenza.

Info

Publication number
MX371154B
MX371154B MX2015008380A MX2015008380A MX371154B MX 371154 B MX371154 B MX 371154B MX 2015008380 A MX2015008380 A MX 2015008380A MX 2015008380 A MX2015008380 A MX 2015008380A MX 371154 B MX371154 B MX 371154B
Authority
MX
Mexico
Prior art keywords
vaccine composition
influenza vaccine
nasal influenza
nasal
adjuvant
Prior art date
Application number
MX2015008380A
Other languages
English (en)
Other versions
MX2015008380A (es
Inventor
Taizou Kamishita
Hideki Hasegawa
Tadaki Suzuki
Akira Ainai
Takashi Miyazaki
Original Assignee
Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By Director General Of Nat Institute Of Infectious Diseases filed Critical Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Publication of MX2015008380A publication Critical patent/MX2015008380A/es
Publication of MX371154B publication Critical patent/MX371154B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a una composición de vacuna para la influenza para administración por atomización a la mucosa nasal, la cual comprende un virión de la influenza entero inactivado y un material de base de gel que comprende polímero de carboxivinilo, la cual se caracteriza porque no comprende un adyuvante.
MX2015008380A 2012-12-28 2013-10-23 Composicion nasal de vacuna para la influenza. MX371154B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012287900 2012-12-28
PCT/JP2013/078721 WO2014103488A1 (ja) 2012-12-28 2013-10-23 経鼻インフルエンザワクチン組成物

Publications (2)

Publication Number Publication Date
MX2015008380A MX2015008380A (es) 2016-03-15
MX371154B true MX371154B (es) 2020-01-20

Family

ID=51020588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008380A MX371154B (es) 2012-12-28 2013-10-23 Composicion nasal de vacuna para la influenza.

Country Status (27)

Country Link
US (2) US20160015800A1 (es)
EP (2) EP3566715A1 (es)
JP (1) JP6247639B2 (es)
KR (1) KR102071099B1 (es)
CN (2) CN104884086A (es)
AU (1) AU2013367751B2 (es)
BR (1) BR112015015523B1 (es)
CA (1) CA2894223C (es)
CY (1) CY1122372T1 (es)
DK (1) DK2939692T3 (es)
ES (1) ES2731899T3 (es)
HK (1) HK1209646A1 (es)
HU (1) HUE044434T2 (es)
IL (1) IL239284B (es)
LT (1) LT2939692T (es)
MX (1) MX371154B (es)
MY (1) MY173503A (es)
NZ (1) NZ708922A (es)
PH (1) PH12015501482B1 (es)
PL (1) PL2939692T3 (es)
PT (1) PT2939692T (es)
RU (1) RU2652296C2 (es)
SG (2) SG10201705190TA (es)
SI (1) SI2939692T1 (es)
TR (1) TR201910293T4 (es)
TW (1) TWI624280B (es)
WO (1) WO2014103488A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603919B2 (en) * 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
LT3162378T (lt) 2014-06-25 2024-03-12 Toko Yakuhin Kogyo Kabushiki Kaisha Gripo vakcinos nazalinė vakcinacijos sistema
JP6322844B2 (ja) 2014-06-25 2018-05-16 東興薬品工業株式会社 医療用シリンジに用いられる点鼻用噴霧ノズル
CN105342982B (zh) * 2015-11-19 2018-08-28 上海现代药物制剂工程研究中心有限公司 经鼻给药的流感疫苗免疫制剂及其制备方法
WO2017090766A1 (ja) * 2015-11-27 2017-06-01 日東電工株式会社 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法
KR101944953B1 (ko) * 2016-07-29 2019-02-01 메타볼랩(주) 점막용 항인플루엔자 바이러스 조성물
US11491219B2 (en) * 2017-10-05 2022-11-08 Tokyo Yakuhin Kogyo Co., Ltd. Nasal hepatitis B vaccine composition and method for producing same
CN114340637A (zh) 2019-07-03 2022-04-12 阿伊里斯株式会社 用于治疗流感病毒感染症的药物组合物
CN113117093B (zh) * 2019-12-31 2024-02-09 辽宁成大生物股份有限公司 一种适用于鼻粘膜递送流感疫苗的促进剂
CA3241333A1 (en) * 2021-12-20 2023-06-29 Taizou Kamishita Vaccine adjuvant agent containing polyacrylic acid polymer and use of same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215739A (en) * 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
JPH0678245B2 (ja) * 1989-07-04 1994-10-05 東興薬品工業株式会社 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤
JP5869744B2 (ja) * 2005-03-23 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用
KR101488025B1 (ko) * 2006-04-21 2015-01-29 도쿄 야쿠힌 고교 가부시키가이샤 스프레이용 겔 타입 피부/점막-부착형 제제 및 이를 이용한투여 시스템
AU2007241829B2 (en) * 2006-04-21 2012-11-29 Shinko Chemical Co., Ltd. Fluid container and airless fluid dispensing system
US9603919B2 (en) 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration

Also Published As

Publication number Publication date
RU2652296C2 (ru) 2018-04-25
CY1122372T1 (el) 2021-01-27
IL239284B (en) 2020-02-27
PL2939692T3 (pl) 2019-10-31
EP2939692A4 (en) 2016-07-06
AU2013367751A1 (en) 2015-07-09
EP2939692B1 (en) 2019-04-24
SI2939692T1 (sl) 2019-10-30
EP3566715A1 (en) 2019-11-13
AU2013367751B2 (en) 2018-02-08
DK2939692T3 (da) 2019-07-08
TWI624280B (zh) 2018-05-21
US20160015800A1 (en) 2016-01-21
TW201427724A (zh) 2014-07-16
CA2894223C (en) 2021-04-06
IL239284A0 (en) 2015-07-30
SG11201504648TA (en) 2015-07-30
CN110038123A (zh) 2019-07-23
MY173503A (en) 2020-01-29
WO2014103488A1 (ja) 2014-07-03
LT2939692T (lt) 2019-08-12
PH12015501482A1 (en) 2015-09-21
JPWO2014103488A1 (ja) 2017-01-12
KR102071099B1 (ko) 2020-01-29
HUE044434T2 (hu) 2019-10-28
BR112015015523B1 (pt) 2023-02-23
CA2894223A1 (en) 2014-07-03
MX2015008380A (es) 2016-03-15
JP6247639B2 (ja) 2017-12-13
PH12015501482B1 (en) 2015-09-21
HK1209646A1 (en) 2016-04-08
KR20150102995A (ko) 2015-09-09
TR201910293T4 (tr) 2019-07-22
RU2015130634A (ru) 2017-02-01
BR112015015523A2 (pt) 2017-07-11
PT2939692T (pt) 2019-06-27
CN104884086A (zh) 2015-09-02
EP2939692A1 (en) 2015-11-04
AU2013367751A8 (en) 2015-08-27
SG10201705190TA (en) 2017-07-28
NZ708922A (en) 2019-10-25
US20190091324A1 (en) 2019-03-28
ES2731899T3 (es) 2019-11-19

Similar Documents

Publication Publication Date Title
PH12015501482A1 (en) Nasal influenza vaccine composition
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
WO2012024621A3 (en) Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
HK1214962A1 (zh) 流感病毒免疫原性組合物及其應用
MX2018007627A (es) Vacuna contra el virus del zika.
IL231547A0 (en) Influenza virus vaccines and their uses
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA201290897A1 (ru) Вакцины для пандемического гриппа
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
MX2019007924A (es) Vacunas contra la influenza.
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
MX343411B (es) Variantes de hemaglutinina y neuraminidasa de influenza.
PH12016502529B1 (en) Influenza vaccine nasal vaccination system
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
HK1201283A1 (en) Influenza c virus and vaccine
BR112022008711A2 (pt) Métodos para produzir uma vacina viral e reduzir o tamanho da partícula viral
RU2010147941A (ru) Иммунологический адъювант на основе наночастиц для вакцин против высокопатогенных штаммов вируса гриппа
MX358262B (es) Vacuna epitopica a partir de un epitope inmunogenico de la neuraminidasa del virus de la influenza ah1n1 y metodo para la obtencion del mismo.
CR20110469A (es) Vacuna inactivada del virus del dengue con un adjuvante libre de aluminio

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration